NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Dividend History

Company News

• NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the grant of inducement share options and restricted stock units to new hires, including the new Chief People Officer. The grants are aimed at incentivizing and retaining key personnel.

  GlobeNewswire Inc.
• NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the closing of a $479.0 million public offering of ordinary shares and pre-funded warrants. The net proceeds will be used to fund the development of the company's lead product, obicetrapib, an oral LDL-lowering therapy.

  GlobeNewswire Inc.
• NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

  NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the pricing of a $416.5 million public offering of ordinary shares and pre-funded warrants. The proceeds will be used to advance the development of the company's lead product candidate, obicetrapib, for the treatment of cardiovascular disease.

  GlobeNewswire Inc.
• NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

  NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the commencement of a $300 million public offering of its ordinary shares and pre-funded warrants. The proposed offering is subject to market conditions and is expected to provide additional funding for the company's development of oral, non-statin medicines for patients at risk of cardiovascular disease.

  GlobeNewswire Inc.
• NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

  NewAmsterdam Pharma announced positive topline data from its Phase 3 BROADWAY trial evaluating obicetrapib, an oral, non-statin medicine for patients with elevated LDL-C. The trial met its primary endpoint, showing a statistically significant reduction in LDL-C compared to placebo, and also observed a 21% reduction in major adverse cardiovascular events.

  GlobeNewswire Inc.